Pfizer's zavzpret nasal spray gains approval for treatment of migraine
Pfizer makes a breakthrough in migraine treatment with the approval from the US FDA of its new drug Zavzpret™ (zavegepant) in the form of a nasal spray, which adds to their current portfolio of oral migraine prevention and treatment therapies.
Zavzpret is a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray, the first of its kind for the treatment of migraine in adults.
The nasal spray was tested in a Phase III clinical trial on patients with migraines with or without auras, and compared to a placebo. The primary end points of the study were taken as freedom from pain and freedom from most bothersome symptoms when measured 2 hours after the provision of the dose. According to monitoring for a secondary end point, pain relief was logged even as quickly as 15 minutes after dosing.
“The FDA approval of zavzpret marks a significant breakthrough for people with migraine who need freedom from pain and prefer alternative options to oral medications,” explained Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business, Pfizer. “Zavzpret underscores Pfizer’s commitment to delivering an additional treatment option to help people with migraine gain relief and get back to their daily lives. Pfizer will continue to build its migraine franchise to further support the billions of people worldwide impacted by this debilitating disease.”
The nasal spray has been rigorously tested in randomized, double-blind, placebo-controlled trials to determine the efficacy, tolerability and safety of zavzpret. In all of these studies, zavzpret demonstrated significantly better outcomes than when compared to a placebo. In the most recent Phase III trial, the results of which were published in The Lancet Neurology, zavzpret showed significantly greater efficacy than the placebo in 13 out of 17 predetermined secondary endpoints. These included time to pian relief and time to normal function as 15–30 minutes and 30 minutes respectively. Other end points also measured were sustained pain freedom and relief after 2–24 hours and 2–48 hours.
“When a migraine hits, it has a significant negative impact on a person’s daily life,” commented Kathleen Mullin, Associate Medical Director at New England Institute for Neurology & Headache. “Among my migraine patients, one of the most important attributes of an acute treatment option is how quickly it works. As a nasal spray with rapid drug absorption, zavzpret offers an alternative treatment option for people who need pain relief or cannot take oral medications due to nausea or vomiting, so they can get back to normal function quickly.”
The safety of the nasal spray was tested, and minor adverse reactions were observed. The most common of which, – taste disorders (includes dysgeusia and ageusia), nausea, nasal discomfort, and vomiting – were seen in around 2% of patients. Hypersensitivity reactions have also occurred in trials involving zavzpret.
The results were analysed by the US FDA and the spray was deemed worthy of approval. Pfizer hopes zavzpret will be available to patients from pharmacies by July 2023.
Related News
-
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Women in Pharma: Marketing for the other half in healthcare
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. This instalment highlights not only the importance of ma... -
News CAR-T therapy for renal cell carcinoma gains fast track approval
Joining the strong number of cancer therapies being approved in 2023 is the CAR-T cell therapy from Invectys, the clinical-stage immuno-oncology company. -
News CPHI Podcast Series: The ripple effects of nearshoring in pharma
In the most recent instalment of the CPHI Podcast Series, Digital Editor Lucy Chard is joined by Sandra Sánchez y Oldenhage, President and CEO of PharmAdvice, to discuss nearshoring and reshoring in the pharmaceutical industry, and the subs... -
News Bringing the pharmaceutical supply chain closer to home
The pharmaceutical supply chain has encountered numerous disruptions in the last few years, impacting procurement, manufacturing, packaging, and distribution operations within the pharmaceutical industry. Read about the rise in calls for near/resh... -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News President Biden's executive order to increase access to contraception
In the USA, President Joe Biden will be signing an executive order to expand access to contraception.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance